Details of the Drug Reposition

General Information of This Drug (ID: DM45HT6)

Drug Name
Glofitamab   DM45HT6
Synonyms RG6062
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Approved [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309
2 ClinicalTrials.gov (NCT04246086) A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma. U.S. National Institutes of Health.